Mesenchymal Stem Cells-Derived Exosomes is under clinical development by CellTex Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesenchymal Stem Cells-Derived Exosomes overview
The therapeutic candidate is under development for the treatment of Alzheimer's disease. The drug candidate comprises exosomes derived from autologous mesenchymal stem cells. It is being developed based on A-1 Exosomes platform.
CellTex Therapeutics overview
CellTex Therapeutics (CellTex) is an adult stem cell laboratory that provides stem cell banking and stem cell infusion services to their clients. It operates a bank to store adult stem cells for medical treatments. CellTex is headquartered in Houston, Texas, the US.
For a complete picture of Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and LoA scores, buy the report here.